Article
Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam.
Therapeutic drug monitoring - 1 Dec 2002
Contin Manuela, Sangiorgi Simonetta, Riva Roberto, Parmeggiani Antonia, Albani Fiorenzo, Baruzzi Agostino
Abstract excerpt
The authors report preliminary findings on the potential contribution of CYP2C19 isoenzyme to the human metabolism of N-desmethylclobazam (N-CLB), the main active metabolite of clobazam (CLB), a benzodiazepine frequently used as add-on therapy in patients with refractory epilepsy. Two children on CLB treatment showing extremely high plasma concentration/dose ratio (C/D) of N-CLB and metabolite/parent drug ratio...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.